
Some light was shined upon this
topic when Dr. Daniel McGehee from the University of Chicago talked about the
neural mechanisms of nicotine reward and aversion when he came to speak at
Loyola University Chicago on February 23rd. He talked about his team’s
paper Nicotine Potentiation of Excitatory
Inputs to Ventral Tegmental Area Dopamine Neurons. He mentioned the prior achievements
of his team, which included reporting that nicotine helped in the induction of long-term
potentiation (LTP) in the ventral tegmental area (VTA) dopamine neurons. This was
done by increasing glutamate release via action of a7 nAChRs on the glutamate
terminals. This showed an important presynaptic contribution of nicotine in LTP
induction (Mao et. al). Simply, they were able to get a deeper understanding of
the effects of nicotine in the ventral tegmental area’s cellular circuits. This
information was used to test the effect of nicotine on excitatory synaptic strength
in the experiment that he presented to us.
After listening to Dr. McGehee’s
talk, I was reminded of an article in the New York Times that had to do with
smoking and (less scientific) methods that people have used to stop smoking,
including behavioral changes as well as different medicines. This article titled,
Taming That Overwhelming Urge to Smoke,
gave more of a layman’s description of what smoking and nicotine do to the
brain and the reward pathway, and how different medications can affect this. It
explained that the nicotine makes the brain feel like the act of smoking is
integral to the survival of the organism. It went on to explain that nicotine isn’t
equally addictive for everyone and that it has to do with that person’s genetics.
Then article mentions a common drug that disguises itself as nicotine and
occupies the brains nicotine receptors (so the real nicotine cannot bind) which
in turn allows it to lessens cravings. But there were some common psychiatric side-effects
with this medicine that made it undesirable.
This article was similar to Dr.
McGehee’s talk in that the discussion of public health was at the center of
both of them. The potential affects of being able to elucidate the mechanism of effect of nicotine
or finding a medicine that could work to stop nicotine addiction could majorly
affect public health and save many people’s lives as well as millions of
dollars in healthcare costs.
References:
Brody, J. E. (2012). Plan to Become an
Ex-Smoker for Good. Retrieved March 04, 2016, from
http://well.blogs.nytimes.com/2012/11/12/plan-to-become-an-ex-smoker-for-good/
Downs, M. (2013). Taming That
Overwhelming Urge to Smoke. Retrieved March 04, 2016, from
http://www.nytimes.com/ref/health/healthguide/esn-smoking-ess.html
Mao, Danyan, Keith Gallagher, and Daniel S. McGehee.
“Nicotine Potentiation of Excitatory Inputs to VTA Dopamine Neurons.” The
Journal of neuroscience : the official journal of the Society for Neuroscience 31.18
(2011): 6710–6720.PMC. Web. 4 Mar. 2016.
No comments:
Post a Comment